In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) compared to 11.0 lbs (5.3%) with oral semaglutide 14 mg, representing a 73.6% greater relative weight loss Lilly has submitted orforglipron to regulators in over 40 countries, with potential U.S. action for obesity in Q2 2026 1,2 For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 INDIANAPOLIS, Feb. 26, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) toda ...

Key Takeaways LLY's Mounjaro and Zepbound generated $36.5B in 2025, about 56% of total revenuesLilly's duo leads U.S. diabetes and obesity new scripts, topping Novo Nordisk's semaglutide drugs.LLY plans to launch its oral GLP-1 orforglipron in the United States in 2026.Eli Lilly’s (LLY) key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Despite being on the market for slightly more than three years, Mounjaro and Zepbound have seen exceptional sales growth, ...

Core Viewpoint - Novo Nordisk is a leader in the GLP-1 drug market, but its stock has underperformed recently, and achieving significant returns over the next decade may be unrealistic due to competitive pressures and market dynamics [1][4][5]. Group 1: Market Position and Products - Novo Nordisk's semaglutide, marketed as Wegovy, Ozempic, and Rybelsus, is among the top-selling GLP-1 therapies, positioning the company well for future growth [3]. - The company has a robust pipeline with several candidates expected to receive approval soon, which could enhance its market position [3][7]. Group 2: Competitive Landscape - Novo Nordisk is losing market share to Eli Lilly, its main competitor, particularly with the performance of its next-generation weight loss drug, CagriSema, which did not outperform Eli Lilly's Zepbound in clinical trials [5][7]. - Increased competition is likely to reduce clinical differentiation and pricing power for Novo Nordisk, limiting its potential upside in the market [7]. Group 3: Financial Outlook - Analysts suggest that even with optimal execution, achieving a compound annual growth rate of 25.89% to turn $100,000 into $1 million is highly unlikely for Novo Nordisk [4]. - The company's revenue is projected to decline year-over-year in 2026, indicating potential challenges ahead [5]. Group 4: Investment Considerations - Despite current struggles, Novo Nordisk's long-standing leadership in the diabetes market and its deep pipeline may present investment opportunities for long-term holders [8][9]. - The company's dividend yield of 4.47% could provide additional returns for investors willing to hold the stock over the next decade [7][9].

Paired with nutrition support, fresh food and easy access to dietitians, Kroger can help customers reach wellness goals CINCINNATI, Feb. 24, 2026 /PRNewswire/ -- The Kroger Co. family of companies and its pharmacies ("Kroger") (NYSE: KR) participates in several savings programs, including those from pharmaceutical manufacturers, which may reduce eligible customers' cost of filling certain GLP-1 medications. Combined with Kroger's broad selection of fresh foods, proteinrich options and personalized support ...

Core Viewpoint - Eli Lilly is launching a multi-dose Zepbound KwikPen to enhance patient retention in the competitive GLP-1 market, aiming to simplify the user experience and streamline distribution logistics [1]. Group 1: Product Launch and Pricing - The new Zepbound KwikPen is designed to deliver four weekly doses of tirzepatide from a single device, replacing the traditional single-dose auto-injector format [1]. - The self-pay starter price for the KwikPen is set at $299 per month, marketed through LillyDirect to minimize cost surprises for patients [1]. - The multi-dose format has received FDA clearance, providing a regulatory basis for the launch beyond mere marketing [1]. Group 2: Strategic Rationale - Eli Lilly's strategy focuses on addressing "injection fatigue," which can lead to higher drop-off rates among patients using GLP-1 drugs for obesity and diabetes management [1]. - The launch of the monthly pen is seen as a retention tool to reduce the hassles associated with weekly injections, thereby encouraging consistent use [1]. - The company aims to control more of the patient journey, from prescribing to affordability, by implementing direct pricing strategies and partnerships to enhance accessibility [1].

GlucaPharm is developing GEP44, a novel, patented peptide (similar in function to Ozempic®, Wegovy®, Mounjaro®, but with reduced risk of adverse events) discovered by researchers at Syracuse University.Vancouver, British Columbia--(Newsfile Corp. - February 23, 2026) - SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) ("SureNano" or the "Company") is pleased to announce that it has completed the acquisition of GlucaPharm Inc. ("GlucaPharm"), a next-generation glucagon-like peptide ("GLP") pharmaceutical com ...

DisclaimerThis article was produced by Moonage Media, a brand / division of MR Solutions Limited (Hong Kong), and is provided for general informational and promotional purposes only. The content does not constitute investment advice, financial advice, medical advice, or a recommendation to buy, sell, or hold any securities, nor does it constitute an offer or solicitation in any jurisdiction.Moonage Media is not a registered broker-dealer, investment adviser, securities analyst, or medical professional. The ...

Core Insights - Hims & Hers Health is exploring new growth avenues as its initial sexual-health product lines reach maturity [1] - The company faced backlash from Novo Nordisk and U.S. regulators following the controversial launch of weight-loss pills [1] Company Overview - Hims & Hers Health is an online telehealth company that has primarily focused on sexual health products [1] - The company is now seeking to diversify its offerings to sustain growth as its original franchises mature [1] Industry Context - The launch of weight-loss pills by Hims & Hers Health has been met with significant criticism, indicating potential regulatory challenges in the telehealth and pharmaceutical sectors [1] - The response from established players like Novo Nordisk highlights the competitive landscape and the scrutiny new entrants may face in the health and wellness market [1]

Core Insights - The article emphasizes the strong investment potential of Flowers Foods (FLO), highlighting its deep value, high and sustainable dividend yield, and significant recovery potential in an improving market environment [1]. Company Analysis - Flowers Foods is noted for its deep value and high dividend yield, which are attractive features for investors [1]. - The company is expected to recover significantly as market conditions improve, indicating a positive outlook for its performance [1]. Analyst Background - The analyst has over a decade of experience researching various industries, including commodities and technology, which adds credibility to the insights provided [1]. - The analyst has transitioned from writing a blog to creating a value investing-focused YouTube channel, showcasing a commitment to thorough research across numerous companies [1].

[Pharmaceuticals][Biotechnology][News Releases in Similar Topics]---- -- CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments [Accessibility Statement] Skip NavigationNext-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapiesREHOVOT, Israel, Feb. 17, 2026 /PRNewswire/ -- [CollPlant Biotechnologies](NASDAQ: CLGN), a regenerative and aesthetic medicine company developing ...